 |
 |
 |
 |
 |
 |
|
||||||
|
SELECT PUBLICATIONS
Basch E et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 2006;7(11):903-9. Abstract
Brahmer JR, Ettinger DS. Non-small cell lung cancer: Adjuvant and neo-adjuvant chemotherapy. Respirology 2007;12(3):320-5. Abstract
Fish-Steagall A et al. Clinical experience with anti-EGFR therapy. Semin Oncol Nurs 2006;22(1 Suppl 1):10-9. Abstract
Fox SW, Lyon DE. Symptom clusters and quality of life in survivors of lung cancer. Oncol Nurs Forum 2006;33(5):931-6. Abstract
Gobel BH. Nursing considerations of bevacizumab use in multiple tumor types. Oncol Nurs Forum 2007;34(3):693-701. Abstract
Heymach JV et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc ASCO 2006;Abstract 7016.
Hirsch FR et al. Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. Proc ASCO 2006;Abstract 7072.
Jackman DM et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(13):3908-14. Abstract
Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91. Abstract
Khoukaz T. Administration of anti-EGFR therapy: A practical review. Semin Oncol Nurs 2006;22(1 Suppl 1):20-7. Abstract
Lobchuk MM et al. Promoting enhanced patient and family caregiver congruence on lung cancer symptom experiences. Oncol Nurs Forum 2006;33(2):273-82. Abstract
Lynch TJ et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007;12(5):610-21. Abstract
Mitchell SA et al. Putting evidence into practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007;11(1):99-113. Abstract
Morse L, Calarese P. EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs 2006;22(3):152-62. Abstract
Natale RB et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. Proc ASCO 2006;Abstract 7000.
Paez JG et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497-500. Abstract
Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract
Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Proc ASCO 2005;Abstract 4.
Sarna L et al. Quality of life and health status of dyads of women with lung cancer and family members. Oncol Nurs Forum 2006;33(6):1109-16. Abstract
Seek A, Hogle WP. Modeling a better way: Navigating the healthcare system for patients with lung cancer. Clin J of Oncol Nurs 2007;11(1):81-5. Abstract
Sequist LV. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 2007;12(3):325-30. Abstract
Sipples R. Common side effects of anti-EGFR therapy: Acneform rash. Semin Oncol Nurs 2006;22(1 Suppl 1):28-34. Abstract
Tsao MS et al. Erlotinib in lung cancer — Molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44. Abstract
Tyagi P. Bevacizumab, when added to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: Preliminary results from the ECOG 4599 trial. Clin Lung Cancer 2005;6(5):276-8. No abstract available.
Veronese ML et al. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): The expanded access protocol experience at the University of Pennsylvania. Cancer Invest 2005;23(4):296-302. Abstract
Wakelee HA et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25(5):472-8. Abstract
William WN et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 18098.
| Table of Contents | Top of Page |
